Anergis Appoints Dr. Vanya Beltrami as Director Product Development
- Former Merck Serono Director brings strong expertise in drug development, product launches and life cycle management -
EPALINGES, Switzerland, June 03, 2014 – Anergis, a company discovering and developing proprietary allergy vaccines, today announced that Vanya Beltrami, PhD, has joined the company as Director Product Development.
Dr. Beltrami brings over 20 years of experience in the pharmaceutical industry with Ares-Serono, Laboratoires Serono SA and Merck Serono SA, where he held several positions with direct product development responsibility (e.g. somatropin), acting as final dosage forms project director and manufacturing product director. Most recently, he was Global Product Team Leader at the Global Product Unit Endocrinology, where he substantially expanded his cross-functional pharmaceutical development experience.
Dr. Beltrami has a long-standing track record in drug product and medical devices development as well as drug launches in multiple countries. His expertise also includes the life cycle management of a brand product generating € 250 M sales per year. Vanya Beltrami was trained as a pharmacist and holds a PhD in Formulation from the University of Geneva.
"We are delighted that Dr. Beltrami has chosen to join our management team as Director Product Development," said Vincent Charlon, CEO of Anergis. "His strong track record and expertise in product development will be of tremendous value to our advanced clinical-stage allergy vaccine pipeline. Most importantly, Mr. Beltrami brings a global approach to product development and is well versed in addressing European and North American regulatory standards."